SG11201402343SA - Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate - Google Patents
Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugateInfo
- Publication number
- SG11201402343SA SG11201402343SA SG11201402343SA SG11201402343SA SG11201402343SA SG 11201402343S A SG11201402343S A SG 11201402343SA SG 11201402343S A SG11201402343S A SG 11201402343SA SG 11201402343S A SG11201402343S A SG 11201402343SA SG 11201402343S A SG11201402343S A SG 11201402343SA
- Authority
- SG
- Singapore
- Prior art keywords
- egfr
- tumors
- resistant
- treatment
- cytotoxic agent
- Prior art date
Links
- 108060006698 EGF receptor Proteins 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 239000002254 cytotoxic agent Substances 0.000 title 1
- 231100000599 cytotoxic agent Toxicity 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161562157P | 2011-11-21 | 2011-11-21 | |
| US201261639452P | 2012-04-27 | 2012-04-27 | |
| PCT/US2012/066205 WO2013078271A1 (en) | 2011-11-21 | 2012-11-21 | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201402343SA true SG11201402343SA (en) | 2014-06-27 |
Family
ID=48470279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402343SA SG11201402343SA (en) | 2011-11-21 | 2012-11-21 | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9233171B2 (xx) |
| EP (1) | EP2794010A4 (xx) |
| JP (1) | JP2014533954A (xx) |
| KR (1) | KR20140105765A (xx) |
| CN (1) | CN104066481A (xx) |
| AU (1) | AU2012340686A1 (xx) |
| BR (1) | BR112014012155A2 (xx) |
| CA (1) | CA2856411A1 (xx) |
| CL (1) | CL2014001282A1 (xx) |
| HK (1) | HK1201772A1 (xx) |
| IL (1) | IL232666A0 (xx) |
| MX (1) | MX2014006087A (xx) |
| PH (1) | PH12014501119A1 (xx) |
| RU (1) | RU2014121820A (xx) |
| SG (1) | SG11201402343SA (xx) |
| WO (1) | WO2013078271A1 (xx) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2632490A4 (en) | 2010-10-29 | 2014-10-22 | Immunogen Inc | NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF |
| EA201390575A1 (ru) | 2010-10-29 | 2014-01-30 | Иммьюноджен, Инк. | Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты |
| CA3115406A1 (en) | 2011-01-24 | 2012-08-02 | National Research Council Of Canada | Antibodies selective for cells presenting egfr at high density |
| RU2014121820A (ru) | 2011-11-21 | 2015-12-27 | Иммьюноджен, Инк. | Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством |
| JP6462673B2 (ja) * | 2013-07-05 | 2019-01-30 | フォーメーション バイオロジックス インコーポレイテッド | Ｅｇｆｒ抗体コンジュゲート |
| EP3044593A4 (en) * | 2013-09-09 | 2017-05-17 | Triact Therapeutics, Inc. | Cancer therapy |
| MX2016006301A (es) | 2013-11-13 | 2016-12-16 | Zymeworks Inc | Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos. |
| KR102322338B1 (ko) | 2014-02-04 | 2021-11-05 | 아스텔라스세이야쿠 가부시키가이샤 | 디아미노헤테로환 카르복스아미드 화합물을 유효 성분으로 하는 의약 조성물 |
| PE20161211A1 (es) * | 2014-03-21 | 2016-11-27 | Abbvie Inc | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr |
| CN109147874A (zh) | 2014-09-02 | 2019-01-04 | 伊缪诺金公司 | 用于配制抗体药物缀合物组合物的方法 |
| US20170333570A1 (en) * | 2014-10-31 | 2017-11-23 | Formation Biologics Inc. | Egfr antibody-based combination therapy |
| KR101692044B1 (ko) * | 2014-12-05 | 2017-01-04 | 사회복지법인 삼성생명공익재단 | 교모세포종에서 표피 성장인자 수용체 억제제의 치료 효과를 예측하는 방법 |
| WO2016191471A1 (en) * | 2015-05-27 | 2016-12-01 | Metastat, Inc. | Method of use for inhibitors of epidermal growth factor receptor variants ii, iii and vi |
| WO2017011618A1 (en) * | 2015-07-15 | 2017-01-19 | The Curators Of The University Of Missouri | Targeted nanoparticle conjugate and method for co-delivery of sirna and drug |
| KR20190138305A (ko) * | 2017-03-31 | 2019-12-12 | 더 큐레이터스 오브 더 유니버시티 오브 미주리 | 약물-내성 종양 치료용 조성물 및 이의 사용 방법 |
| CN107496933B (zh) * | 2017-08-21 | 2019-12-24 | 山东新华制药股份有限公司 | 一种用于治疗胰腺癌的抗体药物偶联物及其制备方法 |
| KR20230106506A (ko) * | 2022-01-03 | 2023-07-13 | 한국생명공학연구원 | Cda 억제제를 포함하는 alk 저해제 내성 비소세포폐암 치료용 조성물 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US5470571A (en) | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| ATE135373T1 (de) | 1989-09-08 | 1996-03-15 | Univ Johns Hopkins | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5459061A (en) | 1990-01-26 | 1995-10-17 | W. Alton Jones Cell Science Center, Inc. | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5558864A (en) | 1991-03-06 | 1996-09-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies |
| DK0628639T3 (da) | 1991-04-25 | 2000-01-24 | Chugai Pharmaceutical Co Ltd | Rekonstitueret humant antistof mod human interleukin-6-receptor |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| US5756291A (en) | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| HU221001B1 (hu) | 1994-03-17 | 2002-07-29 | Merck Patent Gmbh. | Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5942602A (en) | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1999022008A1 (fr) | 1997-10-27 | 1999-05-06 | Sumitomo Electric Industries, Ltd. | Inducteur pour la production d'un anticorps specifique de l'antigene, vecteur d'expression contenant le gene requis a cette fin, et procede pour induire la production de l'anticorps specifique de l'antigene |
| US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| WO2001024763A2 (en) | 1999-10-01 | 2001-04-12 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| PT1242401E (pt) | 1999-11-24 | 2007-03-30 | Immunogen Inc | Agentes citotóxicos compreendendo taxanos e o seu uso terapêutico |
| HUP0204142A3 (en) * | 2000-02-25 | 2004-12-28 | Univ Durham | Anti-egfrviii scfv-antibodies with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| EP1361893B1 (en) | 2001-02-19 | 2012-10-24 | Merck Patent GmbH | Modified anti-egfr antibodies with reduced immunogenicity |
| EP1392359B2 (en) | 2001-05-11 | 2013-03-13 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| MXPA03011365A (es) | 2001-06-13 | 2005-03-07 | Genmab As | Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr). |
| GB0122914D0 (en) | 2001-09-22 | 2001-11-14 | Univ Nottingham | Modulation of stat activity |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| EP1620544B1 (en) | 2003-04-17 | 2018-09-19 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| KR101531400B1 (ko) | 2003-06-27 | 2015-06-26 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도 |
| CN1930187B (zh) * | 2003-06-27 | 2015-08-19 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| EP2221315A1 (en) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| US7935793B2 (en) | 2003-12-04 | 2011-05-03 | Abbott Biotherapeutics Corp. | Treatment of inflammatory bowel diseases with anti-IP-10 antibodies |
| DK1711530T3 (da) | 2003-12-22 | 2009-12-14 | Glaxo Group Ltd | Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme |
| PT1735348E (pt) | 2004-03-19 | 2012-07-24 | Imclone Llc | Anticorpo anti-receptor do factor de crescimento humano |
| DK2447375T3 (da) | 2004-03-31 | 2019-07-29 | Massachusetts Gen Hospital | Fremgangsmåde til bestemmelse af responsiviteten af en tumor på behandlinger med den epidermale vækstfaktor-receptor som mål |
| EP1753463A2 (en) | 2004-06-01 | 2007-02-21 | Genentech, Inc. | Antibody drug conjugates and methods |
| US20070009972A1 (en) | 2005-02-16 | 2007-01-11 | Ginger Chao | Epidermal growth factor receptor polypeptides and antibodies |
| MX2007012817A (es) | 2005-04-15 | 2007-12-12 | Immunogen Inc | Eliminacion de poblacion celular heterogenea o mezclada en tumores. |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| US20090252681A1 (en) | 2005-10-11 | 2009-10-08 | Ablynx N.V. | Nanobodies and Polypeptides Against EGFR and IGF-IR |
| AR063683A1 (es) | 2006-08-11 | 2009-02-11 | Schering Corp | Anticuerpos para il-17a |
| US20090258442A1 (en) | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| CN104013956B (zh) * | 2007-01-25 | 2018-12-18 | 达娜-法勃肿瘤研究所公司 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
| WO2008098145A1 (en) | 2007-02-07 | 2008-08-14 | University Of Washington | Methods for modulating antigen-specific b cell responses |
| NZ578943A (en) | 2007-03-01 | 2012-09-28 | Symphogen As | Recombinant anti-epidermal growth factor receptor antibody compositions |
| US7892777B2 (en) | 2007-07-17 | 2011-02-22 | The Regents Of The University Of Michigan | Methods for measuring whether a treatment affects RPTP-κ activity |
| WO2009030239A1 (en) | 2007-09-06 | 2009-03-12 | Genmab A/S | Novel methods and antibodies for treating cancer |
| US20090269343A1 (en) * | 2008-04-11 | 2009-10-29 | Duke University | Dual Specific Immunotoxin for Brain Tumor Therapy |
| KR101764081B1 (ko) | 2008-04-30 | 2017-08-01 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| CA2722109A1 (en) | 2008-04-30 | 2009-11-05 | Immunogen, Inc. | Potent conjugates and hydrophilic linkers |
| BRPI0910810A2 (pt) | 2008-07-15 | 2019-09-24 | Genentech Inc | conjugados derivados de antraciclina, veículo polimérico, anticorpo, peptídeo ou proteína, veículo t-[cho]m, composições farmacêuticas, métodos de tratamento do câncer ou de distúrbios da proliferação celular, derivado de antraciclina, composto conjugado droga-anticorpo, uso, artigo de manufatura e método de produção de um composto conjugado droga-anticorpo" |
| US8663640B2 (en) | 2008-08-29 | 2014-03-04 | Symphogen A/S | Methods using recombinant anti-epidermal growth factor receptor antibody compositions |
| NZ603623A (en) | 2008-10-10 | 2014-05-30 | Emergent Product Dev Seattle | Tcr complex immunotherapeutics |
| JP5593488B2 (ja) | 2008-11-17 | 2014-09-24 | 独立行政法人国立がん研究センター | 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療 |
| EP2486023A4 (en) * | 2009-10-06 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| CN103003424B (zh) | 2010-05-18 | 2015-05-13 | 株式会社医学生物学研究所 | 结合转化生长因子α且对Ras基因突变的癌具有增殖抑制活性的抗体 |
| EA201390575A1 (ru) | 2010-10-29 | 2014-01-30 | Иммьюноджен, Инк. | Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты |
| EP2632490A4 (en) | 2010-10-29 | 2014-10-22 | Immunogen Inc | NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF |
| RU2014121820A (ru) | 2011-11-21 | 2015-12-27 | Иммьюноджен, Инк. | Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством |
-
2012
- 2012-11-21 RU RU2014121820/15A patent/RU2014121820A/ru not_active Application Discontinuation
- 2012-11-21 WO PCT/US2012/066205 patent/WO2013078271A1/en active Application Filing
- 2012-11-21 CA CA2856411A patent/CA2856411A1/en not_active Abandoned
- 2012-11-21 JP JP2014542584A patent/JP2014533954A/ja active Pending
- 2012-11-21 KR KR1020147016745A patent/KR20140105765A/ko not_active Application Discontinuation
- 2012-11-21 AU AU2012340686A patent/AU2012340686A1/en not_active Abandoned
- 2012-11-21 SG SG11201402343SA patent/SG11201402343SA/en unknown
- 2012-11-21 US US13/682,948 patent/US9233171B2/en not_active Expired - Fee Related
- 2012-11-21 MX MX2014006087A patent/MX2014006087A/es not_active Application Discontinuation
- 2012-11-21 CN CN201280056769.4A patent/CN104066481A/zh active Pending
- 2012-11-21 EP EP12850911.4A patent/EP2794010A4/en not_active Withdrawn
- 2012-11-21 BR BR112014012155A patent/BR112014012155A2/pt not_active IP Right Cessation
-
2014
- 2014-05-15 CL CL2014001282A patent/CL2014001282A1/es unknown
- 2014-05-18 IL IL232666A patent/IL232666A0/en unknown
- 2014-05-19 PH PH12014501119A patent/PH12014501119A1/en unknown
-
2015
- 2015-03-10 HK HK15102403.0A patent/HK1201772A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013078271A1 (en) | 2013-05-30 |
| JP2014533954A (ja) | 2014-12-18 |
| AU2012340686A1 (en) | 2014-06-19 |
| EP2794010A4 (en) | 2015-10-21 |
| US20130156796A1 (en) | 2013-06-20 |
| MX2014006087A (es) | 2014-08-01 |
| IL232666A0 (en) | 2014-07-31 |
| CA2856411A1 (en) | 2013-05-30 |
| BR112014012155A2 (pt) | 2017-05-30 |
| CL2014001282A1 (es) | 2014-11-14 |
| HK1201772A1 (en) | 2015-09-11 |
| RU2014121820A (ru) | 2015-12-27 |
| KR20140105765A (ko) | 2014-09-02 |
| CN104066481A (zh) | 2014-09-24 |
| US9233171B2 (en) | 2016-01-12 |
| PH12014501119A1 (en) | 2014-08-04 |
| EP2794010A1 (en) | 2014-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1201772A1 (en) | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate egfr egfr | |
| IL281714A (en) | Methods for increasing the effectiveness of FOLR1 cancer therapy | |
| IL228738A0 (en) | Antibodies for cancer treatment | |
| HK1254859A1 (zh) | 治療乳腺癌的方法 | |
| HK1203091A1 (en) | Methods for diagnosis of lung cancer | |
| IL228741A0 (en) | A method for egfr-targeted combined cancer therapy | |
| EP2760452A4 (en) | METHODS OF TREATING CANCER | |
| IL232530B (en) | A combination of factors for cancer treatment | |
| EP2885002A4 (en) | BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES | |
| EP2752198A4 (en) | PREPARATION OF VACCINE FOR THE TREATMENT OF CANCER | |
| HK1202240A1 (en) | Methods of treating cancer | |
| EP2700652A4 (en) | DIAGNOSIS AND TREATMENT OF CANCER BY ANTI-ITM2A ANTIBODIES | |
| EP2788378A4 (en) | ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER | |
| HK1199261A1 (en) | Methods for treatment of diseases | |
| PL2550296T3 (pl) | Przeciwciała monoklonalne w leczeniu nowotworów | |
| EP2670435A4 (en) | USE OF ANTI-DKK1 MONOCLONAL ANTIBODY FOR THE TREATMENT OF LIVER CANCER | |
| HK1207870A1 (en) | Anti-human sema4a antibodies useful to treat disease sema4a | |
| EP2849786A4 (en) | METHOD FOR THE TREATMENT OF GASCULAR CANCER | |
| IL230479A0 (en) | A method of treating cancer through the combined use of drugs | |
| HK1213584A1 (zh) | 用於治療癌症的 抗體及方法 | |
| EP2797628A4 (en) | METHODS OF TREATING BREAST CANCER NOT RESPONDING TO TRASTUZUMAB | |
| IL237229A0 (en) | Methods of treating cancer using lipoplatin | |
| EP2755679A4 (en) | IMMUNOGENS INDUCING CYTOTOXIC T LYMPHOCYTES FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER | |
| IL232266A0 (en) | Cancer treatment methods |